S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mar

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Matthew Seymour, MD: A Clinical Trialist’s Perspective

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Hypofractionated Locoregional RT in Early Breast Cancer

Melanoma-Specific Survival With Sentinel Lymph Node Biopsy

Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy

AMA Survey Finds Rapid Growth in Physician AI Adoption